Large Granular Lymphocytic Leukemia Market
Number of pages: 100 | Report Format: PDF | Published date: March 02, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 2.38 billion |
|
Revenue Forecast in 2031 |
US$ 7.63 billion |
|
CAGR |
13.82% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global large granular lymphocytic leukemia market was valued at US$ 2.38 billion in 2022 and is expected to register a revenue CAGR of 13.82% to reach US$ 7.63 billion by 2031.
Large Granular Lymphocytic Leukemia Market Fundamentals
Large granular lymphocytic (LGL) leukemia is a chronic mature lymphoproliferative disorder of the T/NK lineage. Majorly, there are two kinds of LGL: T-LGL leukemia and aggressive NK-cell leukemia. This classification system was approved by the World Health Organization (WHO) in 2001. T-LGL leukemia and chronic NK-cell lymphocytosis share clinical and biological characteristics and treatment options.
While the cause of LGL leukemia is unknown, a genetic alteration or mutation, often to the STAT3 and STAT5b genes, is linked to the disorder. The percentage of people with LGL leukemia with a history of autoimmune diseases ranges from 10% to 40%. However, some research also suggests that rheumatoid arthritis is frequently linked to LGL leukemia. Both types of LGL leukemia develop slowly. People above 60 years are generally more prone to developing this disease. Medical professionals can treat LGL leukemia; however, occasionally, the disease persists and can develop into a chronic health problem.
Most individuals diagnosed with chronic T-cell and NK-cell LGL leukemia show similar symptoms, such as a reduction in red blood cell synthesis (anemia) affecting around half of the patients and a low concentration of neutrophils, a kind of white blood cell. Moreover, other serious symptoms include ongoing infections, fever, sweating at night, unintended weight loss, and splenomegaly.
[5754675]
Large Granular Lymphocytic Leukemia Market Dynamics
The increasing prevalence of LGL leukemia is a prominent factor driving revenue growth in the global market. According to the National Organization for Rare Disorders estimates, in 2022, about 0.2 to 0.72 instances of large granular lymphocytes were expected in the U.S. among every 1,000,000 people. However, this number may be low as individuals without symptoms or those with the disease in its early stages remain undetected.
Increasing research and development for LGL leukemia is also a potential factor to fuel the market revenue growth during the forecast period. For instance, current research predicted that several clinical reports had shown connections between the frequency of LGL leukemia and stem cells, bone marrow, and solid organ transplantation. Also, LGL leukemia is likely to go undiagnosed among people with rheumatoid arthritis, highlighting the importance of further research.
The presence of pipeline drugs is also expected to boost revenue growth in the global large granular lymphocytic leukemia market. Moreover, the market revenue growth is also influenced by the support from several non-profit organizations that help underinsured individuals with LGL leukemia. For instance, the Leukemia & lymphoma society acts as a voice for all blood cancer patients seeking access to high-quality, fairly priced, coordinated treatment. It contributes money for lifesaving blood cancer research around the world. It also offers free information and support services.
However, the global large granular lymphocytic leukemia market may experience limited revenue growth in middle-income countries, such as the Middle East and Africa, where healthcare standards are not advanced. This is mainly due to the high prices of drugs and therapies for treating LGL leukemia.
Large Granular Lymphocytic Leukemia Market Ecosystem
The global large granular lymphocytic leukemia market has been analyzed from three perspectives: drug class, distribution channel, and region.
Large Granular Lymphocytic Leukemia Market by Drug Class
[854674]
Based on the drug class, the global large granular lymphocytic leukemia market has been segmented into antineoplastics, immunosuppressants, alkylating agents, monoclonal antibodies, and other drug classes.
The antineoplastics segment dominated the global large granular lymphocytic leukemia market with the largest revenue share in 2022. Antineoplastic drugs are used as the first line of treatment for LGL leukemia. Antineoplastics drugs prevent cell proliferation and cancer from spreading, improving the survival rates of people with LGL leukemia. Moreover, the side effects of these drugs are generally mild than other drugs. The cost of antineoplastics drugs can also be comparatively lower, making them a more viable option for patients. Moreover, studies have shown that antineoplastic drugs have been able to reduce the size of tumors and have also been found to reduce the risk of relapse in LGL leukemia patients.
The monoclonal antibodies segment is anticipated to show the highest revenue growth during the forecast period. This is majorly attributed to the recommendation of monoclonal antibodies as second-line treatment for LGL leukemia. Additionally, the revenue growth of monoclonal antibodies is influenced by many pipeline monoclonal antibody drugs. Moreover, these drugs are highly effective in targeting malignant cells and can be combined with traditional chemotherapy to reduce the risk of relapse. Furthermore, they have fewer side effects than traditional therapies, which can benefit cancer patients. This aside, monoclonal antibodies undergo many new advancements for treating LGL leukemia.
Large Granular Lymphocytic Leukemia Market by Distribution Channel
Based on the distribution channel, the global large granular lymphocytic leukemia market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounts for most of the global large granular lymphocytic leukemia market revenue share. Hospital pharmacies offer drugs with guaranteed quality, affordable costs, information access, and proper drug guidance. The high footfall of patients in hospitals also supports the segment revenue growth.
Large Granular Lymphocytic Leukemia Market by Region
Based on the region, the global large granular lymphocytic leukemia market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America leads the global granular lymphocytic leukemia market owing to the increased prevalence of LGL leukemia. LGL leukemia is most frequently reported in patients from North America; half of them also have autoimmune disorders, such as rheumatoid arthritis. Moreover, the presence of many players involved in developing drugs for LGL leukemia is also supporting market revenue growth in North America. Increasing research and development for advancing diagnosis and treatment for LGL leukemia also aids the global large granular lymphocytic leukemia market revenue growth.
The market in Europe is characterized by increasing healthcare standards offering better diagnosis and treatment. Moreover, the global large granular lymphocytic leukemia market is expanding due to an increase in support by regional governments for LGL research and development initiatives.
The large granular lymphocytic leukemia market in Asia Pacific is likely to grow at a high revenue CAGR during the forecast period. This is due to increased healthcare standards and the launch of new diagnosis and treatment options. Moreover, government initiatives to provide funding for the treatment of LGL leukemia are propelling market revenue growth.
Large Granular Lymphocytic Leukemia Market Competitive Landscape
Leading players are focusing on strategies, such as the adoption of recent technology, product developments, mergers and acquisitions, joint ventures, alliances, and partnerships to increase their revenue share in the large granular lymphocytic leukemia market. Focused research and development efforts enable companies to develop innovative products and a broad pipeline of potential new medicines, leading to revenue growth and helping to secure their brand image.
The prominent players in the global large granular lymphocytic leukemia market include:
Large Granular Lymphocytic Leukemia Market Strategic developments
The high prevalence of the disease and advancements in treatment and diagnosis are projected to fuel revenue growth in the global large granular lymphocytic leukemia market.
Some prominent players in the global large granular lymphocytic leukemia market include Bristol Myers Squibb and Company, GSK Plc, Sanofi SA, and Emcure Pharma.
The monoclonal antibodies segment is anticipated to grow rapidly during the forecast period.
Asia Pacific is expected to mark the highest revenue growth during the forecast period.
The high cost of drugs and low healthcare standards in middle-income countries are the most prominent restraints in the global large granular lymphocytic leukemia market.
*Insights on financial performance are subject to the availability of information in the public domain